Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 2, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will present at the 42nd Annual...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: FVT TDS Source Type: news